Cooperative Agreement U10CA037404

Cooperative Agreement Summary Wake Forest University Health Sciences received a $248,194 Cooperative Agreement from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded May 1, 2025, with a completion date of April 30, 2028. This award supports a preparatory phase for a multisite clinical trial focused on improving collaboration between radiation oncologists and radiologists in cancer treatment planning and surveillance. The primary...

Federal Cooperative Agreement Summary The Georgia Center for Oncology Research and Education, Inc. received a $1.37 million Cooperative Agreement from the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) under the Organized Approaches to Increase Colorectal Cancer Screening program (CFDA 93.800), effective August 30, 2025, through August 29, 2030. The Georgia Colorectal Cancer Control Program (GCRCCP) delivers evidence-based colorectal cancer screening...

Federal Cooperative Agreement Award Summary Awarded by the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), MedStar Health Research Institute Inc. received $2,677,863 on July 25, 2025, to develop and test implementation strategies for delivering practical geriatric assessment in community oncology settings. The project addresses a critical gap in cancer care for older adults, who will comprise 75% of the 22.2 million projected U.S. cancer...

Cancer Immunoprevention Network Resource Coordinating Center Health Research, Inc. (Roswell Park Division) received a $1.65 million Cooperative Agreement from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) beginning September 1, 2025, through August 31, 2030. The awardee will serve as the Data and Resource Coordinating Center (DRCC) for the Cancer Immunoprevention Network (CIP-NET), providing centralized administrative infrastructure, data...

The National Cancer Institute (NCI) awarded Columbia University's Herbert Irving Comprehensive Cancer Center (HICCC) a Project Grant totaling $193,926 under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025 through August 31, 2030. This grant supports the development and implementation of investigator-led clinical trials within the NCI Clinical Trials Network (NCTN), Experimental Therapeutics Clinical Trials Network (ETCTN), and NCI Community Oncology Research...

Federal Cooperative Agreement Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $225,511 Cooperative Agreement award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective March 16, 2026, with a completion date of February 29, 2028. The award supports the development and validation of a plasma-based multimodal digital polymerase chain reaction (PCR) assay to detect androgen receptor (AR) somatic...

Federal Cooperative Agreement Summary The University of Miami received a $4.67 million Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Centers Support Grants program (CFDA 93.397), awarded on September 5, 2025, with a completion date of August 31, 2030. The award funds the PROMISE (Personalized Outreach and Multifaceted Interventions for Screening Enhancement) initiative, which addresses disparities in anal cancer and cervical cancer prevention, screening, and...

Cooperative Agreement Summary: CP-CTNET Coordinating Center The University of Wisconsin–Madison received a $2.49M Cooperative Agreement from the National Cancer Institute under the Cancer Control program (CFDA 93.399) awarded August 5, 2025, through July 31, 2031. This award funds the Cancer Prevention Clinical Trials Network (CP-CTNET) Coordinating Center, which serves as the second phase of the National Cancer Institute's three-part cancer prevention development strategy. The coordinating...

The Oregon Health & Science University (OHSU) received a $596,996 Cooperative Agreement from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), effective April 1, 2026, through February 29, 2028. This award supports the BUNDLE (Bundled Outreach of Multiple Cancer Screenings for Under-Screened Populations) study, a collaborative initiative between OHSU's Knight Cancer Institute, the Oregon Rural Practice-Based Research Network, and the...

Federal Cooperative Agreement Summary The University of Chicago received a $1,368,982 Cooperative Agreement award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective May 1, 2025 through April 30, 2030. The award supports development of a non-invasive blood-based diagnostic tool for early detection of prostate, lung, colorectal, and ovarian cancers. The research leverages the 5-hydroxymethylcytosine-selective exonuclease...